European Cystic Fibrosis Society (ECFS)
Published on European Cystic Fibrosis Society (ECFS) (https://www.ecfs.eu)

Home > KALYDECO (ivacaftor)

KALYDECO (ivacaftor)

Date:
Friday, July 27, 2012

Vertex Receives European Approval for KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People With a Specific Genetic Mutation (G551D)

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the European Commission has approved KALYDECO™ (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Further information in the press release, online here [1]

Terms & Conditions Privacy policy  Accessibility Sitemap Contact 
© EUROPEAN CYSTIC FIBROSIS SOCIETY 2025. All rights reserved. Website by VidaVia (link is external)
European Cystic Fibrosis Society (ECFS)

Source URL:https://www.ecfs.eu/news/kalydeco-ivacaftor

Links
[1] http://investors.vrtx.com/releasedetail.cfm?ReleaseID=696069